Alphatec Holdings, Inc. (ATEC) Q3 2026 earnings review
Alphatec expands its profit margins, but cuts its sales outlook
Alphatec signed up more spine surgeons and widened its profit margins, but weaker bone-graft sales forced a full-year outlook cut. Third-quarter revenue rose 13% to $221 million as surgical case volumes grew 20%. However, Chief Executive Pat Miles said lower attachment of biologics — bone-graft materials used in surgery — caused sales to miss management's plan, and by our math the new outlook has revenue growth slowing to 10% in the fourth quarter.
| Revenue | $221.2M +12.6% from a year ago |
|---|---|
| Surgical revenue per case | -5% by our math, on +20% case volume |
| Adjusted EBITDA margin | 17.3% +4 percentage points from a year ago |
| Full-year revenue outlook | Cut $20M to ~$862M; free cash flow halved to ~$10M |
⚖️ Verdict: 🔴 Bearish
The story got worse because falling revenue per surgery broke the second-half growth plan and halved the full-year free cash flow target to $10 million. For two quarters management held its surgical sales target despite lower prices and mix per procedure, but a roughly 5% drop in revenue per case by our math plus another imaging equipment shortfall forced cuts across revenue, operating cash profit and cash flow. One bright spot: cost discipline lifted the EBITDA margin, excluding one-offs, by 4 percentage points.
The question now is whether the bone-graft shortfall is a fixable sales execution slip or structural hospital pushback on bundle pricing. If sales reps can restore attachment rates, 25% growth in new surgeons will pull revenue growth back toward the mid-teens; if per-case revenue keeps falling, procedure growth will not be enough to hit next year's $1 billion revenue goal. Fourth-quarter surgical revenue per case will tell.
🐂 Bull Case
Lower Overhead Lifted Profit Margins Four Points
Alphatec is turning higher sales into profit even while revenue misses its plan. Earnings before interest, taxes, depreciation and amortization (EBITDA), excluding one-offs, rose 46% from a year ago to $38.3 million, lifting that margin by 4 percentage points to 17.3%. The spine surgery company also posted $3.2 million in standard operating income, reversing a $15.9 million loss a year ago.
The gain came from both product margins and lower overhead. Gross margin, excluding one-offs, rose 1.8 percentage points to 71.9%. At the same time, sales, general and administrative costs — advertising, sales commissions and corporate overhead — fell by 3.4 percentage points of revenue to 59.9%, while research and development spending dropped 1.4 points to 8.1%.
What to watch: fourth-quarter EBITDA margin against the 17.9% rate implied by the full-year outlook. Holding that level despite slower sales growth would show that cost discipline can protect earnings.
Surgeon Adoption and Hardware Demand Stayed Strong
Doctors continue to adopt Alphatec's spine surgery systems at a rapid clip. Net new surgeon users grew 25% from a year ago, accelerating from 24% last quarter against the toughest comparison of the year. Those doctors drove a 20% increase in surgical case volumes, matching the second quarter's pace.
Core spine implants also held up well. Surgical hardware revenue rose 17% from a year ago, adding $26 million and accounting for all of the surgical division's $25 million dollar growth, Chief Executive Pat Miles said. That proves the third-quarter revenue miss came from add-on bone graft materials rather than hospitals rejecting the company's implants.
What to watch: net new surgeon user growth in the fourth quarter. Staying above 20% would support double-digit procedure growth into next year even if average revenue per surgery stays weak.
Positives this quarter didn't test
Two standing growth drivers received no updated figures in the third-quarter earnings release because management typically details them on the conference call and in the quarterly filing.
- EOS Insight software pull-through: implant sales at hospitals using the surgical planning software rose 32% within six months of activation as of last quarter; the call will test whether fleet adoption moved above 15–20%.
- International expansion: revenue in markets outside the US, led by Japan and Australia, grew 17% last quarter; the quarterly filing will show whether international sales kept outpacing domestic growth.
🐻 Bear Case
Weak Biologics Sales Cut Revenue Per Surgery
"Third-quarter revenue fell short of our expectations, primarily due to lower biologics attachment," Chief Executive Pat Miles said. Biologics are bone-graft materials used during spine fusion to help bone heal. While hardware sales rose $26 million, total surgical revenue rose $25 million to $202 million, meaning biologics sales shrank.
The shortfall widened the gap between procedure volume and revenue. Case volumes grew 20% from a year ago while surgical revenue rose 14%, so average revenue per surgery fell about 5% by our math, worse than the roughly 3% decline in the first half. Miles said "improving biologics performance is a clear priority for us" ahead of launching OsteoAdapt, an experimental bone-graft protein in clinical trials.
What to watch: fourth-quarter surgical revenue per case on the earnings call. Another drop near 5% would show that doctors are using fewer of the company's bone-graft products even as they perform more surgeries.
Second Outlook Cut Lowers Sales and Cash Plans
Alphatec lowered its full-year revenue forecast for the second time this year and cut its profit and cash targets for the first time. Three months ago, the medical device maker held its $882 million revenue target and raised its profit view; this quarter, both core surgery and EOS, its low-radiation imaging system, fell short.
- Full-year total revenue: cut $20 million to $862 million, pointing to 10.5% growth in Q4 by our math
- Full-year surgical revenue: cut $16 million to $789 million, pointing to 12.1% growth in Q4 by our math
- Full-year EOS imaging revenue: cut $4 million to $73 million after Q3 brought in about $19 million by our math
- Full-year free cash flow: halved from at least $20 million to about $10 million
The cuts show that the second-half acceleration management planned for did not happen. Instead of speeding up to 18% growth in the second half, surgical revenue slowed from 17% in the first half to 14% in the third quarter.
What to watch: fourth-quarter revenue against the $235 million implied by the new full-year plan. A miss there would put next year's $1 billion revenue goal out of reach without a major rebound.
Instrument Spending and Debt Repayment Drained Cash
Alphatec generated $6 million in free cash flow in the third quarter, hitting the top of its $4 million to $6 million plan. Across the first nine months of the year, however, free cash flow remains negative $4 million by our math after a $10 million cash drain in the first half.
Expanding the surgical business still requires heavy upfront spending on trays of surgical instruments and implants placed in hospitals. Inventories on the balance sheet climbed to $206.9 million, up 24% from a year ago and nearly double the pace of revenue growth. Meanwhile, repaying maturing convertible debt in July reduced short-term debt by $59.2 million since December, leaving $79.9 million in cash and $594.7 million in long-term liabilities.
What to watch: fourth-quarter free cash flow against the $14 million implied by the $10 million full-year target. Hitting it requires a fourth-quarter cash haul 75% higher than last year's $8 million.
Risks this quarter didn't answer
Two standing concerns could not be checked from the earnings release alone and await the conference call or the third-quarter filing.
- Valence navigation system placements: management has not disclosed how many hospitals have installed its new surgical workflow system or whether rivals' robotics bundles are slowing adoption.
- Related-party supplier payables: the quarterly filing's footnote will show whether unpaid bills to an affiliate of board-linked Squadron Capital rose further from $10.9 million in June.
💲 Other KPIs
Unpaid bills to suppliers edged down slightly from $62.1 million in the second quarter, but remain up 67.1% from $36.9 million a year ago and up 50.7% since December. Stretching supplier payments helped fund the $37.4 million inventory build across the first nine months and supported operating cash flow.
The share count rose 4.0% from 151.4 million a year ago as employee stock awards vested, slightly slower than the 4.5% growth rate in the second quarter. Stock-based compensation fell 14.8% from a year ago to $14.0 million, or 6.3% of revenue, while stockholders' equity remained in a $2.3 million deficit.
🔮 Guidance
Cut. The spine company lowered its full-year revenue plan by $20 million, to about 13% growth from 15% previously. By our math, that leaves $235.2 million for the fourth quarter, or 10.5% growth from a year ago — down from 12.6% in the third quarter. It is the second reduction this year after an $8 million trim in the first quarter: -$8M, $0M, -$20M.
Cut. Management reduced the surgical target by $16 million after holding it at $805 million for two quarters, lowering expected full-year growth from 17% to 15%. By our math, the new figure leaves $212.9 million for the fourth quarter, or 12.1% growth vs 14.0% in the third quarter, as lower bone-graft attachment weighs on average revenue per procedure.
Cut. The imaging system forecast dropped by $4 million following an $8 million cut in the first quarter from the initial $85 million target. By our math, third-quarter EOS sales were about $19 million, down 4.2% from a year ago, leaving $22.5 million for the fourth quarter — a 2.2% decline from last year's fourth quarter.
Cut. The full-year operating cash profit plan moved down $3 million, reversing half of last quarter's $6 million raise: +$4M, $0M, +$6M, -$3M. The target still represents 46.9% growth from last year and a 15.9% full-year margin. By our math, it leaves $42.1 million for the fourth quarter, or a 17.9% margin vs 17.3% in the third quarter.
Cut. Alphatec halved its full-year cash generation target after holding the $20 million floor for three quarters. With nine-month free cash flow at negative $4 million by our math ($10 million used in the first half and $6 million generated in Q3), the new outlook still requires $14 million of free cash flow in the fourth quarter.
❓ Key Questions
Why did bone-graft attachment drop in the third quarter?
Chief Executive Pat Miles blamed the revenue miss on lower biologics attachment after saying in the second quarter that attachment had stabilised. Investors need to know whether hospital price pushback, sales force focus, or rival products drove the drop.
Are the $1 billion 2027 revenue and cash targets intact?
With the 2026 revenue plan cut to $862 million and fourth-quarter growth slowing to 10.5% by our math, reaching $1 billion next year would require growth to re-accelerate to 16%. Management has not said whether the 2027 targets still stand.
What is the dollar revenue base of EOS Insight accounts?
Management has cited a 32% implant sales lift at hospitals using EOS Insight software, yet surgical revenue slowed to 14% and EOS capital revenue was cut again. Sizing that lift requires the number of live accounts and their baseline spending.
How much of the payables balance is owed to Squadron?
Accounts payable sit at $61.6 million, up $20.7 million since December. Because unpaid bills to an affiliate of board-linked Squadron Capital rose to $10.9 million in the first half, the third-quarter filing needs to show how much cash flow relied on related-party credit.